President Joe Biden’s administration on Thursday unveiled its promised initiative aimed at cutting drug prices, saying it will test new ways to reduce such costs for the Medicare health insurance program including tying payments for medications to their effectiveness. The …
Drugmakers including Pfizer Inc., Sanofi SA, and GlaxoSmithKline Plc plan to raise U.S. prices on more than 300 drugs in the United States on Jan. 1, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors. The …
The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries. …
The chair of a House of Representatives committee and a fellow Democratic committee member on Monday urged Jaguar Health Inc. to reverse recent price hikes of a drug that could be used to treat side effects in COVID-19 patients and …
A University of California at Berkeley study has found that a “reference pricing model” — comparing brand name and generic medications and adjusting co-pays to encourage patients to choose the lowest cost drugs — delivers “significant cost-savings that increase over …
Drugmakers including Bristol-Myers Squibb Co., Gilead Sciences Inc., and Biogen Inc. hiked U.S. list prices on more than 50 drugs on Wednesday, bringing total New Year’s Day drug price increases to more than 250, according to data analyzed by healthcare …
The top Republican and Democrat on the U.S. Senate Finance Committee announced a proposal to lower prescription drug prices on Tuesday that could save $100 billion in costs to government healthcare programs, and said the committee would vote on the …
U.S. states filed a lawsuit accusing Teva Pharmaceuticals USA Inc. of orchestrating a sweeping scheme with 19 other drug companies to inflate drug prices – sometimes by more than 1,000% – and stifle competition for generic drugs, state prosecutors said …
A bipartisan group of U.S. senators re-introduced a bill on Tuesday aimed at helping generic drug companies bring out a cheaper version of pharmaceuticals. Makers of branded drugs have long been accused of refusing to provide samples of drugs on …
The U.S. government’s proposal to eliminate rebates that pharmacy benefit managers receive from drugmakers will not have a meaningful impact on growth, and does not affect the commercial market, Cigna Corp. Chief Executive Officer David Cordani said on Friday. Investors …
